Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We reported a case of gastric cancer with peritoneal dissemination, which was successfully treated by neoadjuvant chemotherapy and partial gastrectomy. A 71-year-old female visited to our hospital because of umbilical tumor (Sister Mary Joseph's node). UGI series showed a Borrmann 1 type gastric cancer and laparoscopic examination revealed peritoneal metastasis. Her abdominal cavity was treated with MTX and CDDP and she was given intravenous administration of 5-FU/LV. Repeated laparoscopy revealed complete disappearance of peritoneal seeding, and a partial gastrectomy was done. The histopathological findings of resected specimen showed the significant effects of preoperative chemotherapy. She has been living for more than 2 years with no recurrence after initial chemotherapy.
 ...
PMID:[Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy]. 782 66

A 75-year-old man with gastric cancer having multiple liver metastases was given intraarterial infusion therapy with sequential low-dose MTX (30 mg/body) and 5-FU (1,000 mg/body) for metastatic liver tumors one month after the primary gastric tumor was resected. This therapy was given once a week on admission and every two weeks while an outpatient. A total of 18 courses of this therapy produced marked regression and necrosis of liver metastases. The effect was thus rated as partial response. This patient survived 15 months after surgery. These results indicate that intraarterial infusion therapy with sequential low-dose MTX and 5-FU may be effective in multiple liver metastasis from gastric cancer.
 ...
PMID:[A case report: multiple liver metastasis from gastric cancer responding to intraarterial infusion of sequential low-dose MTX and 5-FU]. 794 34

Cancer chemotherapy plays a central role in the treatment of recurrent or unresectable scirrhous gastric cancers classified mainly as Borrmann type 4. Though we have no specifically effective drugs for scirrhous gastric cancer, 5-FU and its derivative, MMC, anthracyclines, CDDP, CQ and ACNU are known to be relatively effective single agents against this tumor. In an attempt to enhance the effect of single agents, several combined chemotherapy regimens have been devised and tested. These regimens included 5-FU + MMC, UFT + MMC, UFT + CDDP, MTX.5-FU, FAM, FAP, EAP and ELF regimen. At present, combined therapies using 5-FU and MTX or CDDP may be the most attractive of these combined regimens.
 ...
PMID:[Chemotherapy of scirrhous gastric cancer]. 794 83

A case of an 81-year-old male with Borrmann II type was reported. The lesion was diagnosed histologically as undifferentiated adenocarcinoma. Biochemically modulated chemotherapy preceded by administration of Methotrexate (MTX) and followed by 5-fluorouracil (5-FU) was given to him. The procedure was weekly intermediate-dose therapy consisting of MTX 100 mg (i.v.) followed 3 hours later by 5-FU 600 mg (i.v.) with leucovorin rescue in the following 2 days. After this treatment was repeated 6 times, advanced gastric cancer disappeared on endoscopic and histological findings, so the patient was regarded as showing a complete response. Ths, this biochemically modulated chemotherapy was thought to be in effective method against gastric cancer.
 ...
PMID:[A case of gastric cancer completely responding to sequential methotrexate and 5-fluorouracil therapy]. 808 54

A 70-year-old-male was diagnosed as having gastric cancer (Borr. 2, 78 mm in size on the body region; mod. dif. adenocarcinoma). CT scan revealed direct invasion of the liver. A course of MTX/5-FU sequential therapy was started (MTX 100 mg/m2, 5-FU 500 mg/m2, i.v., weekly; interval, 2 hours) on March 23, 1992. The gastric tumor showed 67% reduction on week 8 and 86% on week 10. The liver invasion had almost disappeared by CT scan (total doses, MTX 1,040 mg, 5-FU 6,750 mg). On June 25, the tumor was completely resected by radical.gastrectomy. The pathological specimen showed a "submucosal carcinoma" (10 mm in size, Stage I). Twenty-two months after the operation, the patient is alive and in good health. No cancer recurrence has been found without post-operative chemotherapy.
 ...
PMID:[Neoadjuvant chemotherapy for elderly advanced gastric cancer: a case report of MTX/5-FU sequential therapy followed by radical gastrectomy]. 808 55

An advanced gastric cancer patient with multiple retroperitoneal lymph node metastases and bone metastases was treated with sequential MTX and 5-FU. Complete response was obtained against both gastric primary lesion and retroperitoneal lymph nodes observed endoscopically and by computed tomography. Partial response was obtained against bone metastases observed by bone scintigraphy. Side effects of the chemotherapy were not observed.
 ...
PMID:[A case of nonresectable gastric cancer treated by sequential methotrexate and 5-fluorouracil]. 829 4

Three cases of acute myeloid leukemia associated with inv(16(p13q22) were followed up for over 5 years. This chromosome aberration is generally thought to be a good prognostic factor. However, it is also reported that these patients are apt to relapse and have relatively high frequency of central nervous system (CNS) involvement. The first patient (M4Eo), who died of gastric cancer about 5 years after the initial treatment without frank relapse, did not have prophylactic therapy for CNS involvement. The second patient (M5b) developed meningeal leukemia and myeloblastoma of the brain, showing similar findings on CT scan to cases reported by Holms et al. He was treated successfully with whole brain irradiation and intrathecal injection of ara-C and MTX, and intracranial tumor disappeared on CT and MR imaging. He has been enjoying a good quality of life without any complication for over ten years after the initial diagnosis. The third patient (M4Eo) relapsed once but reentered complete remission with relative ease and we used an intrathecal injection prophylactically. This case has been followed up as an outpatient for more than 5 years since onset. On the basis of these findings, it may be concluded that these leukemia patients with inv(16)(p13q22) have good prognosis and can be cured with chemotherapy.
 ...
PMID:[Long term follow-up of three cases of acute myeloid leukemia associated with inv(16)(p13q22)]. 841 49

In a 63-year-old male patient with gastric cancer having multiple liver metastases, the metastatic lesions responded well to postoperative staggered intraarterial infusion therapy with MTX and 5-FU. The intraarterial infusion therapy was administered once a week. A total of 5 courses of this therapy produced marked regression of liver metastases and remarkable necrosis. The effect was thus rated as PR. The patient is healthy and has been successfully rehabilitated. His dose is oral 5-FU (200 mg x 2).
 ...
PMID:[A case report: multiple liver metastasis of gastric cancer responding to intraarterial infusion of MTX and 5-FU]. 851 33

Intra-aortic infusion chemotherapy by low-dose sequential MTX/5-FU was performed in 46 advanced or recurrent gastric cancer patients. Partial response was found in 13 cases (28%). The major lesion of 13 responders was inoperable Borrmann Type 4 gastric cancer in 4 cases, peritoneal recurrence with an abdominal wall in 6 cases, recurrence in the abdominal mass in 2 cases and Douglas pouch in one. The mean duration of effectiveness in the responders was 6.7 months and the median survival time was 19 months after the treatment. The side effects were mainly related to the digestive organs, but the symptoms were mild. Leucopenia of grade 3 and 4 was found in 6 (13%) and thrombocytopenia of grade 2 in one patient. Arterial infusion chemotherapy by sequential MTX/5-FU proved to be effective in poorly differentiated and signet ring cell carcinoma, such as Borrmann type 4 gastric cancer.
 ...
PMID:[Arterial infusion chemotherapy for advanced gastric cancer by sequential MTX/5-FU]. 885 81

We analyzed the clinical response, toxicities, out-patient and overall survival time among 41 gastric cancer patients with peritoneal metastasis to evaluate chemotherapies and drug delivery routes. Sixteen patients were treated by arterial infusion (AI) and 25 by systemic therapy (ST), with either 5-FU/MTX (FMTX) therapy or 5-FU/CDDP (FP) therapy. Partial response was observed in 8 patients (50%) among 16 with AI and in 6 (24%) among 25 with ST (p = 0.09). There were no differences in the incidence of side effects (> or = grade 2 according to WHO criteria) between AI and ST group, at 25% and 36%, respectively. No significant differences were observed in either survival time or home care duration among patients with AI chemotherapy and those with ST procedure.
 ...
PMID:[A study of arterial infusion chemotherapy for gastric cancer patients with peritoneal metastasis]. 885 82


<< Previous 1 2 3 4 5 6 7 8 Next >>